Increased Efficiency and Production with QIS™
The Tc-99m QIS™ platform allows for significant production volumes of the isotope at the cyclotron site. With two hour dissolution and purification along with little long term waste, the ARTMS Tc-99m solution will be there in times of supply shortages or as you bridge between generator cycles, instantly making your site more efficient and keeping your operations running smoothly.
Produce Technetium-99m Without a Generator
The Tc-99m supply chain has experienced significant challenges over the last 20 years and is in need of a viable, decentralized alternative to reactor based production for use in generators. ARTMS’ technology meets that need and has shown substantial production volume on low energy cyclotrons. ARTMS was founded with the Intention of ensuring that all patients that need Tc-99m studies can get them, regardless of supply chain challenges.
- ARTMS supplies a single use, Molybdenum-100 targets with either Copper or Tantalum backing.
- At an optimal irradiation energy of 24 MeV and 500 uA, a 6 hour irradiation will yield up to 37 Ci of Technetium-99m at the end of bombardment of the solid target.
- Dissolution and purification process takes approximately 2 hours.
- ARTMS is approved by Health Canada for cyclotron produced Technetium-99m and is actively seeking approval in other regulatory jurisdictions.
Technetium-99m (Tc-99m) is the most commonly used medical isotope In the world. There are millions of Tc-99m studies done annually for cardiac, neurologic, pulmonary and other disease states. Tc-99m will remain the workhorse isotope for Nuclear Medicine.